Impact of an intensive facility-community case management intervention on 6-month HIV outcomes among select key and priority populations in Uganda.


Journal

AIDS research and therapy
ISSN: 1742-6405
Titre abrégé: AIDS Res Ther
Pays: England
ID NLM: 101237921

Informations de publication

Date de publication:
05 12 2022
Historique:
received: 08 05 2022
accepted: 14 11 2022
entrez: 5 12 2022
pubmed: 6 12 2022
medline: 11 12 2022
Statut: epublish

Résumé

Key and priority populations (with risk behaviours and health inequities) are disproportionately affected by HIV in Uganda. We evaluated the impact of an intensive case management intervention on HIV treatment outcomes in Kalangala District, predominantly inhabited by fisher folk and female sex workers. This quasi-experimental pre-post intervention evaluation included antiretroviral therapy naïve adults aged ≥ 18 years from six health facilities in the pre-intervention (Jan 1, 2017-December 31, 2017) and intervention phase (June 13, 2018-June 30, 2019). The primary outcomes were 6-month retention and viral suppression (VS) before and after implementation of the intervention involving facility and community case managers who supported participants through at least the first three months of ART. We used descriptive statistics to compared the characteristics, overall outcomes (i.e., retention, lost to follow up, died), and VS of participants by phase, and used mixed-effects logistic regression models to determine factors associated with 6-month retention in care. Marginal (averaging over facilities) probabilities of retention were computed from the final multivariable model. We enrolled 606 and 405 participants in the pre-intervention and intervention phases respectively. Approximately 75% of participants were aged 25-44 years, with similar age and gender distributions among phases. Approximately 46% of participants in the intervention were fisher folk and 9% were female sex workers. The adjusted probability of 6-month retention was higher in the intervention phase, 0.83 (95% CI: 0.77-0.90) versus pre-intervention phase, 0.73 (95% CI: 0.69-0.77, p = 0.03). The retention probability increased from 0.59 (0.49-0.68) to 0.73 (0.59-0.86), p = 0.03 among participants aged 18-24 years, and from 0.75 (0.71-0.78) to 0.85 (0.78-0.91), p = 0.03 among participants aged ≥ 25 years. VS (< 1,000 copies/mL) was approximately 87% in both phases. After implementation of the case management intervention, we observed significant improvement in 6-month retention in all age groups of a highly mobile population of predominantly fisher folk.

Identifiants

pubmed: 36471321
doi: 10.1186/s12981-022-00486-9
pii: 10.1186/s12981-022-00486-9
pmc: PMC9724352
doi:

Substances chimiques

Anti-HIV Agents 0

Types de publication

Journal Article Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

62

Informations de copyright

© 2022. The Author(s).

Références

J Int AIDS Soc. 2021 Jul;24 Suppl 3:e25716
pubmed: 34190412
Top Antivir Med. 2011 Feb-Mar;19(1):12-6
pubmed: 21852711
AIDS Care. 2017 Feb;29(2):263-267
pubmed: 27461407
AIDS Behav. 2018 Jan;22(1):146-153
pubmed: 28916898
PLoS One. 2013 Aug 05;8(8):e70770
pubmed: 23940638
Sex Transm Infect. 2011 Oct;87(6):511-5
pubmed: 21835763
BMJ Open. 2012 Jul 04;2(4):
pubmed: 22763661
AIDS. 2019 Jul 15;33(9):1467-1476
pubmed: 30964750
J Acquir Immune Defic Syndr. 2017 Jun 1;75 Suppl 2:S140-S148
pubmed: 28498183
AIDS. 2005 Mar 4;19(4):423-31
pubmed: 15750396
J Public Health Policy. 2015 May;36(2):153-69
pubmed: 25811386
BMC Res Notes. 2018 Oct 25;11(1):762
pubmed: 30359290
EClinicalMedicine. 2020 Jan 05;18:100231
pubmed: 31922120
J Acquir Immune Defic Syndr. 2008 Apr 15;47(5):597-606
pubmed: 18285714
Lancet HIV. 2016 Aug;3(8):e388-e396
pubmed: 27470029
MMWR Morb Mortal Wkly Rep. 2018 Jun 15;67(23):663-667
pubmed: 29902168
Bull World Health Organ. 2010 Sep 1;88(9):681-8
pubmed: 20865073
JAMA. 2019 Feb 5;321(5):451-452
pubmed: 30629090
PLoS One. 2020 Jul 31;15(7):e0236801
pubmed: 32735566
AIDS Care. 2014;26(3):282-91
pubmed: 23941609
AIDS Behav. 2016 Oct;20(10):2464-2476
pubmed: 26961380
Stat Methods Med Res. 2007 Jun;16(3):219-42
pubmed: 17621469
J Acquir Immune Defic Syndr. 2013 Nov 1;64 Suppl 1:S33-41
pubmed: 23982662
Curr Opin HIV AIDS. 2018 May;13(3):212-219
pubmed: 29570471
SAHARA J. 2018 Dec;15(1):138-145
pubmed: 30257611
Ann Intern Med. 2012 Jun 5;156(11):817-33, W-284, W-285, W-286, W-287, W-288, W-289, W-290, W-291,
pubmed: 22393036
Lancet HIV. 2020 Oct;7(10):e699-e710
pubmed: 32888413
Sex Transm Dis. 2012 Jun;39(6):433-9
pubmed: 22592828
Med Care. 2000 Jan;38(1):58-69
pubmed: 10630720
Matern Child Health J. 2015 Sep;19(9):2029-37
pubmed: 25656728

Auteurs

David B Meya (DB)

Infectious Diseases Institute, College of Health Sciences, Makerere University, Mulago Hill Road, 22418, Kampala, Uganda. david.meya@gmail.com.
Department of Medicine and International Health, University of Minnesota, Minneapolis, MN, USA. david.meya@gmail.com.
School of Medicine, College of Health Sciences, Makerere University, Kampala, Uganda. david.meya@gmail.com.

Agnes N Kiragga (AN)

Infectious Diseases Institute, College of Health Sciences, Makerere University, Mulago Hill Road, 22418, Kampala, Uganda.

Elizabeth Nalintya (E)

Infectious Diseases Institute, College of Health Sciences, Makerere University, Mulago Hill Road, 22418, Kampala, Uganda.

Grace Banturaki (G)

Infectious Diseases Institute, College of Health Sciences, Makerere University, Mulago Hill Road, 22418, Kampala, Uganda.

Joan Akullo (J)

Infectious Diseases Institute, College of Health Sciences, Makerere University, Mulago Hill Road, 22418, Kampala, Uganda.

Phillip Kalyesubula (P)

Infectious Diseases Institute, College of Health Sciences, Makerere University, Mulago Hill Road, 22418, Kampala, Uganda.

Patrick Sessazi (P)

Infectious Diseases Institute, College of Health Sciences, Makerere University, Mulago Hill Road, 22418, Kampala, Uganda.

Hillary Bitakalamire (H)

Kalangala District Health Services, Kalangala, Uganda.

Joseph Kabanda (J)

U.S Centers for Disease Control and Prevention, Kampala, Uganda.

Julius N Kalamya (JN)

U.S Centers for Disease Control and Prevention, Kampala, Uganda.

Alice Namale (A)

U.S Centers for Disease Control and Prevention, Kampala, Uganda.

Moses Bateganya (M)

U.S Centers for Disease Control and Prevention, Atlanta, GA, USA.

Joseph Kagaayi (J)

Rakai Health Sciences, Program, Rakai, Uganda.
Makerere School of Public Health, College of Health Sciences, Makerere University, Kampala, Uganda.

Steve Gutreuter (S)

U.S Centers for Disease Control and Prevention, Atlanta, GA, USA.

Michelle R Adler (MR)

U.S Centers for Disease Control and Prevention, Kampala, Uganda.

Kiren Mitruka (K)

U.S Centers for Disease Control and Prevention, Atlanta, GA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH